[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Contribution
August 2, 2006

Approaches to Screening for Intimate Partner Violence in Health Care Settings: A Randomized Trial

Author Affiliations

Author Affiliations: Department of Psychiatry and Behavioural Neurosciences (Drs MacMillan, Wathen, Boyle and Mss Jamieson and Webb), Department of Pediatrics (Dr MacMillan), and Department of Emergency Medicine (Dr Worster), McMaster University, Hamilton, Ontario; Department of Epidemiology and Biostatistics, University at Albany—State University of New York (Dr McNutt); and Department of Family Medicine, The University of Western Ontario, London (Dr Lent).

JAMA. 2006;296(5):530-536. doi:10.1001/jama.296.5.530

Context Screening for intimate partner violence (IPV) in health care settings has been recommended by some professional organizations, although there is limited information regarding the accuracy, acceptability, and completeness of different screening methods and instruments.

Objective To determine the optimal method for IPV screening in health care settings.

Design and Setting Cluster randomized trial conducted from May 2004 to January 2005 at 2 each of emergency departments, family practices, and women's health clinics in Ontario, Canada.

Participants English-speaking women aged 18 to 64 years who were well enough to participate and could be seen individually were eligible. Of 2602 eligible women, 141 (5%) refused participation.

Intervention Participants were randomized by clinic day or shift to 1 of 3 screening approaches: a face-to-face interview with a health care provider (physician or nurse), written self-completed questionnaire, and computer-based self-completed questionnaire. Two screening instruments—the Partner Violence Screen (PVS) and the Woman Abuse Screening Tool (WAST)—were administered and compared with the Composite Abuse Scale (CAS) as the criterion standard.

Main Outcome Measures The approaches were evaluated on prevalence, extent of missing data, and participant preference. Agreement between the screening instruments and the CAS was examined.

Results The 12-month prevalence of IPV ranged from 4.1% to 17.7%, depending on screening method, instrument, and health care setting. Although no statistically significant main effects on prevalence were found for method or screening instrument, a significant interaction between method and instrument was found: prevalence was lower on the written WAST vs other combinations. The face-to-face approach was least preferred by participants. The WAST and the written format yielded significantly less missing data than the PVS and other methods. The PVS and WAST had similar sensitivities (49.2% and 47.0%, respectively) and specificities (93.7% and 95.6%, respectively).

Conclusions In screening for IPV, women preferred self-completed approaches over face-to-face questioning; computer-based screening did not increase prevalence; and written screens had fewest missing data. These are important considerations for both clinical and research efforts in IPV screening.

Trial Registration clinicaltrials.gov Identifier: NCT00336297